{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/07/30/3335900/0/en/EyePoint-Completes-Enrollment-of-Both-Pivotal-Phase-3-Trials-of-DURAVYU-for-Treatment-of-Diabetic-Macular-Edema-DME.html", "message": "News view counter 857811 successfully enlarged"}